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1. Introduction
Background:
Matrivax R&D Corp. is a start-up biotechnology company with R&D 
operations located in Boston, USA and full access to a vaccine pilot 
manufacturing facility in Haikou, China.  We are developing a proprietary 
vaccine process that entraps polysaccharides in a cross-linked protein 
‘carrier’ or matrix, termed Protein Capsular Matrix Vaccine (PCMV), as an 
alternative to conjugate vaccine technology.  Despite highly efficacious 
pneumococcal conjugate vaccines , eg., Prevnar®, S. pneumoniae causes > 
1 million deaths worldwide annually. Likewise, typhoid fever afflicts ~16 
million people, resulting in 600,000 deaths despite effective vaccines such 
as Typhim Vi® and Vivotif ® (Ty21a).  Inexpensive, efficacious 
polysaccharide vaccines that elicit TH-cell ‘memory’ will actively displace 
their unconjugated and conjugated vaccine counterparts. Towards this end, 
Matrivax is actively research and developing pneumococcal, enteric fever, 
and meningococcal PCMV candidates.
Summary of Results:
1)   ‘Optimized’ PCMV chemical reaction conditions improve
polysaccharide incorporation into protein matrices,
2)   Fractionation of PCMV particles by size-exclusion chromatography                           
significantly increases immunopotency (Section 3),
3)  ‘Optimized’ PPS14 PCMVs containing 1.5% or 6% the amount of PPS14 
antigen contained in Prevnar® elicits a comparable anti-PPS14  
antibody response in a murine immunogenicity model (Section 4),
4)   PCMV immunization elicits an immune response suggestive of
memory (Section 5), 
5) S. Typhi Vi antigen is captured in a DNI PCMV,
6) Immunization with Vi PCMV elicited ~8 fold higher specific response
compared to immunization with Typhim Vi® (Section 6).    
Development of Protein 
Capsular Matrix Vaccine 
(PCMV) Technology
Thanawastien, A., Griffin, T., and K. P. Killeen
650 Albany Street
Boston, MA USA
5. PPS14 PCMV Elicits Memory Immune Response
Following a boost ~ 7 months after PCMV primes there is an 
increase in GMT at 4 days which continues to rise at 21 days (top 
panel, table) compared to PS immunized animals.  More specific 
IgG is induced in PCMV-immunized animals compared to PS 
immunized animals (bottom panel, graph).
Mice were immunized on Day 0, 14, and 28 and then boosted on Day 239.  Anti-
PPS14 IgG and IgM responses were assayed 4 days and 21 days post-boost.
6. Unoptimized Vi-DNI PCMV Immunogenicity
Mice were immunized on Day 0, 14, and 28. Sera was collected 10-12 
days after each immunization and assayed for anti-Vi responses by ELISA.  
Immunization with an unoptimized Vi-DNI PCMV elicits ~8 
fold higher anti-VI IgG GMT than immunization with Vi PS 
alone.
7. Vi-PCMV Typhoid Fever Vaccine Next Steps
Apply optimized reaction conditions to Vi-PCMV
Evaluate addional matrix proteins, e.g. CRM197
Size-fractionate Vi-CRM197 PCMV particles and evaluate immunogenicity
Finalize 10L scale expression conditions and purify S. Typhi-derived Vi and 
C. diphtheriae CRM197 and technology transfer to Haikou
3. Optimization of PCMV process
4. Preclinical comparison of PCMV to Prevnar®
Result:  Anti-PPS14 IgG GMT from PPS14-DNI PCMV-
immunized animals is comparable to that of Prevnar-
immunized animals at either 6% the dose (top panel) or 
1.5% the dose (bottom panel) of PPS14 contained in 
Prevnar.
Day 39 anti-PPS14 IgG titers showing mean/standard error of the 
mean (left panel) and GMT (right panel) from mice immunized with 
PCMVs and Prevnar.
Day 39 anti-PPS14 IgG titers showing mean/standard error of the 
mean (left panel) and GMT (right panel) from mice immunized with 
PCMVs and Prevnar.
Reaction parameters & particle sizing:
1) alter reactant proportions and reaction time
2) new cross-linking agents
3) alternative homologous and heterologous protein
matrices
4) size fractionate particles
2. PCMV Concept
Issues associated with conjugate vaccines:
1) relatively high cost of goods (COGs),
2) limitation in the number of PS serotypes that can be incorporated
(reduced breadth of protection); and
3)   each PS require different conjugation chemistry with carrier
protein
Alternative approach:  Protein Capsular Matrix Vaccine (PCMV) 
technology may allow multiple PS incorporation ‘cocktail’ which will 
streamline manufacture, enabling addition of increased serotypes, 
and reduce COGs.
9. Conclusions and Future Direction
8. Vaccine Technologies Institute (VTI)
Haikou China pilot vaccine facility
1) 3,000 square meters facility
2)   Three parallel production suites (each certified for 
BL2 containment), 50 and 150 L fermentation 
capacity, polysaccharide purification, formulation, 
and filling
3) Projected completion date February 2010/   
Validation underway
High-titer antibody response elicited against 
particle sized PPS14- and unoptimized Vi-
PCMVs; anamnestic/memory immune 
response induced  
In vitro and in vivo ‘proof-of concept’ 
demonstrated with anthrax and tularemia 
PCMV (functional antibody elicited with 
pneumococcal and meningococcal antigen 
PCMV; data not shown)
Developing Vi, pneumococcal, and CRM197 
expression and purification processes for 
technology transfer to Haikou
GMP manufacture scheduled 4Q10 in Haikou 
Enteric fever Vi antigen based PCMV Phase 1 
trial 2011
